Epidural blockade affects the pharmacokinetics of propofol in surgical patients
| ISRCTN | ISRCTN14865526 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14865526 |
| Clinical Trials Information System (CTIS) | 2010-020050-34 |
| Protocol serial number | N/A |
| Sponsor | Leiden University Medical Center (Netherlands) |
| Funder | Leiden University Medical Center, Department of Anesthesiology (Netherlands) |
- Submission date
- 16/01/2014
- Registration date
- 30/01/2014
- Last edited
- 30/01/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Surgery
Plain English summary of protocol
Background and study aims
It still remains unclear why an epidural or spinal analgesia (an injection given into the back that numbs the lower half of the body and stops any pain being felt) reduces the need for sedatives.
The study aims to find the relationship between epidural analgesia and reduction in the need for sedatives.
Who can participate?
You can participate in the study if you are between 18 and 65 years old, are relatively healthy and are scheduled for surgery under epidural analgesia and sedation or anaesthesia.
What does the study involve?
Participants were randomly allocated to one of four groups. One group received dummy medication, and the other three groups received three different doses of ropivacaine in the epidural space (an area of the spinal column). Everybody received the same dosage of propofol sedation to induce a certain level of sleep.
What are the possible benefits and risks of participating?
There are no benefits in participating. The study requires an extra line in the arm and could result in bruises. The study would take up 150 minutes of the participants time before the scheduled operation.
Where is the study run from?
Leiden University Medical Center, Netherlands.
When is the study starting and how long is it expected to run for?
The study started in December 2010 and completed in February 2012.
Who is funding the study?
Leiden University Medical Center, Department of Anesthesiology, Netherlands.
Who is the main contact?
M.E. Sitsen, MD, mesitsen@lumc.nl
J Vuyk, MD, PhD, J.Vuyk@lumc.nl
A.Dahan, MD, PhD, a.dahan@lumc.nl
Contact information
Scientific
Albinusdreef 2
Leiden
2333 ZA
Netherlands
| Phone | +31 715 262301 |
|---|---|
| mesitsen@lumc.nl |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized double-blind placebo-controlled study design, single centre |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | The influence of epidural blockade with ropivacaine on the pharmacokinetics and pharmacodynamics of propofol sedation in patients |
| Study objectives | We hypothesized that epidural blockade would affect the pharmacokinetics of propofol and that altered hemodynamics may be involved. We therefore studied the influence of epidural blockade on the pharmacokinetics of propofol in a double-blind randomized manner. |
| Ethics approval(s) | Medical Ethics Committee, Leiden University Medical Center, 28/07/2010, ref.: T10.087.NL32295.058.10 |
| Health condition(s) or problem(s) studied | The effect of epidural analgesia with ropivacaine on the pharmacokinetics and pharmacodynamics of propofol in patients |
| Intervention | 28 patients were randomly assigned to one of four study groups. After written informed consent the patients received an intravenous cannula, a lumbar epidural catheter at L2-L3, placed 5 cm in the epidural space after skin infiltration with lidocaine, and an intra-arterial canulla in the radial artery for hemodynamic monitoring and blood sampling. The patient is then attached to the standard peri-operative anaesthetic monitoring. This includes a 3-lead ECG, blood pressure monitoring, pulse oximetry (SaO2), and cerebral activity registration through BIS monitoring. The cardiac output was monitored noninvasively. The patients in group 1 received no ropivacaine (10 ml of epidural NaCl 0.9%), the patients in group 2 received 50 mg of epidural ropivacaine 7.5 mg/ml, the patients in group 3 received 100 mg of epidural ropivacaine 7.5 mg/ml and the patients in group 4 received 150 mg of ropivacaine 7.5 mg/ml. During the 30 minutes after the medication was given data were gathered; it took 30-40 minutes to achieve a steady block level. Thereafter patients received a target controlled infusion with propofol with an initial target concentration of 1 µg/ml. After 6, 12 and 18 min this target propofol concentration was increased to 2.5 µg/ml, 4 µg/ml and 6 µg/ml. Twenty-four min after the start of the propofol administration the administration was terminated. After waking up, depending on the time available before scheduled surgery, the patient was monitored and samples were taken until 90-120 min after termination of the propofol sedation. The study was ended and the epidural catheter was used to administer ropivacaine at a dose sufficient for surgery. Patients were then continued for the scheduled surgical procedure. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Ropivacaine, propofol |
| Primary outcome measure(s) |
To evaluate the influence of epidural blockade with ropivacaine on the pharmacokinetics of propofol. |
| Key secondary outcome measure(s) |
To evaluate the influence of epidural blockade with ropivacaine on the pharmacodynamics of propofol. This includes both the sedative and the hemodynamic effects. |
| Completion date | 03/02/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 65 Years |
| Sex | All |
| Target sample size at registration | 28 |
| Key inclusion criteria | 1. American Society of Anesthesiologists (ASA) class I-II 2. Age 18-65 years 3. Patients scheduled for surgery requiring epidural anaesthesia and sedation |
| Key exclusion criteria | 1. Patients with a body mass index (BMI) >30 2. Participation in a trial on investigational drugs within 3 months prior to the study 3. Known history of hepatic, renal disease or other disease as judged by the investigators 4. Bleeding or coagulation disorders 5. Patients receiving chronic analgesic therapy 6. Patients using alpha-blockers 7. Pregnancy or lactation 8. Alcohol or drug abuse or history of alcohol/drug abuse 9. Documented or suspected soybean protein and/or drug allergy 10. Allergy for amide-type local anesthetics |
| Date of first enrolment | 13/12/2010 |
| Date of final enrolment | 03/02/2012 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
2333 ZA
Netherlands
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
